AstraZeneca Hints At Acquisitions, Merck And Novo Nordisk React To China Cuts – Emerging Market Earnings Roundup (Part 3)
This article was originally published in PharmAsia News
AstraZeneca plans to enhance capacity in emerging markets while cutting jobs and consolidating operations. Merck sees strong volume growth in China, and Novo Nordisk reports a slow quarterly sales growth in the Chinese human insulin market.
You may also be interested in...
AstraZeneca is to slash 12% of its workforce in the next three years, as the company forecasts declining revenues in 2012 because of its steep patent cliff, government pricing interventions and R&D pipeline failures.
GSK Sees Enduring Pricing Pressure Unlikely, Novo Projects Lower Growth In China, Lilly Bolsters Diabetes Presence In India: Emerging Markets Round Up (Part 1)
In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets. In Q3, earnings in emerging markets were slightly down for GlaxoSmithKline PLC, Novo Nordisk A/S, and Eli Lilly & Co, mostly due to increased pricing pressure as well as increased competition in the diabetes market, with local players rapidly gaining market share..
AstraZeneca PLC has announced a plan to invest $200 million to build a new manufacturing plant inside Taizhou, Jiangsu-based China Medical City